Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 22:2024:5590805.
doi: 10.1155/2024/5590805. eCollection 2024.

Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry

Anthony J Weekes  1 , Ariana Trautmann  1 , Parker L Hambright  1 , Shane Ali  1 , Angela M Pikus  1 , Nicole Wellinsky  1 , Kelly L Goonan  1 , Sarah Bradford  2 , Nathaniel S O'Connell  3
Affiliations

Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry

Anthony J Weekes et al. Crit Care Res Pract. .

Abstract

Objectives: To characterize the association between pulmonary embolism (PE) severity and bleeding risk with treatment approaches, outcomes, and complications.

Methods: Secondary analysis of an 11-hospital registry of adult ED patients treated by a PE response team (August 2016-November 2022). Predictors were PE severity and bleeding risk. The primary outcome was treatment approach: anticoagulation monotherapy vs. advanced intervention (categorized as "immediate" or "delayed" based on whether the intervention was received within 12 hours of PE diagnosis or not). Secondary outcomes were death, clinical deterioration, and major bleeding.

Results: Of the 1832 patients, 139 (7.6%), 977 (53.3%), and 9 (0.5%) were classified as high-risk, intermediate-high, intermediate-low, and low-risk severity, respectively. There were 94 deaths (5.1%) and 218 patients (11.9%) had one or more clinical deterioration events. Advanced interventions were administered to 86 (61.9%), 195 (27.6%), and 109 (11.2%) patients with high-risk, intermediate-high, and intermediate-low severity, respectively.Major bleeding occurred in 61/1440 (4.2%) on ACm versus 169/392 (7.6%) with advanced interventions (p <0.001): bleeding withcatheter-directed thrombolysiswas 19/145 (13.1%) versus 33/154(21.4%) with systemic thrombolysis,p= 0.07. High risk was twice as strong as intermediate-high risk for association with advanced intervention (OR: 5.3 (4.2 and 6.9) vs. 1.9 (1.6 and 2.2)). High risk (OR: 56.3 (32.0 and 99.2) and intermediate-high risk (OR: 2.6 (1.7 and 4.0)) were strong predictors of clinical deterioration. Major bleeding was significantly associated with advanced interventions (OR: 5.2 (3.5 and 7.8) for immediate, 3.3 (1.8 and 6.2)) for delayed, and high-risk PE severity (OR: 3.4 (1.9 and 5.8)).

Conclusions: Advanced intervention use was associated with high-acuity patients experiencing death, clinical deterioration, and major bleeding with a trend towards less bleeding with catheter-directed interventions versus systemic thrombolysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Study flow diagram.
Figure 2
Figure 2
Predicted probability of each treatment approach.
See this image and copyright information in PMC

References

    1. Konstantinides S. V., Meyer G., Becattini C., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) European Heart Journal . 2020;41(4):543–603. doi: 10.1093/eurheartj/ehz405. - DOI - PubMed
    1. Kearon C., Akl E. A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest . 2016;149(2):315–352. doi: 10.1016/j.chest.2015.11.026. - DOI - PubMed
    1. Kahn S. R., de Wit K. Pulmonary embolism. New England Journal of Medicine . 2022;387(1):45–57. doi: 10.1056/NEJMcp2116489. - DOI - PubMed
    1. Stevens S. M., Woller S. C., Kreuziger L. B., et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest . 2021;160(6):e545–e608. doi: 10.1016/j.chest.2021.07.055. - DOI - PubMed
    1. Ortel T. L., Neumann I., Ageno W., et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances . 2020;4(19):4693–4738. doi: 10.1182/bloodadvances.2020001830. - DOI - PMC - PubMed

LinkOut - more resources